Keywords
glecaprevir,Mavyret,abt-493,hepatitis c treatment,direct-acting antiviral,ns3/4a protease inhibitor,c38h46n6o9,c38h46n6o9,structural formula,chemical structure,structural formula,carboxylic acid,amide bond,benzofuran ring,imidazole ring,pyrrolidine ring,dimethylamino group,methoxy group,ns3/4a protease inhibitor,antiviral,hepatitis c,virus inhibition,pibrentasvir,replication inhibition,direct-acting antiviral mechanism,viral protease inhibition,hcv lifecycle interference,rna virus targeting,carbon,hydrogen,nitrogen,oxygen,single bonds,double bonds,aromatic bonds,antiviral pharmacology,hepatitis c treatment,direct-acting antivirals,ns3/4a protease inhibitors,pharmaceutical chemistry,drug design,therapy,therapeutics,pharmacodynamics,pharmacokinetics,combination therapy,ns3/4a protease,hepatitis c virus,viral protease,hcv genotype targeting,direct-acting antiviral agents,chronic hepatitis c,glecaprevir pharmacology,drug metabolism,structural,formula,chemical compound,structural chemistry,bond,line bond,charge,proj-creative-abx-24q2,proj-creative-abx-24q2-novartis,Glecaprevir